Endoscopic mucosal resection for treatment of early gastric cancer

H Ono, H Kondo, T Gotoda, K Shirao, H Yamaguchi, D Saito, K Hosokawa, T Shimoda, S Yoshida

Abstract

Background—In Japan, endoscopic mucosal resection (EMR) is accepted as a treatment option for cases of early gastric cancer (EGC) where the probability of lymph node metastasis is low. The results of EMR for EGC at the National Cancer Center Hospital, Tokyo, over a 11 year period are presented.

Methods—EMR was applied to patients with early cancers up to 30 mm in diameter that were of a well or moderately histologically differentiated type, and were superficially elevated and/or depressed (types I, IIa, and IIc) but without ulceration or definite signs of submucosal invasion. The resected specimens were carefully examined by serial sections at 2 mm intervals, and if histopathology revealed submucosal invasion and/or vessel involvement or if the resection margin was not clear, surgery was recommended.

Results—Four hundred and seventy nine patients with early gastric cancer were treated by EMR from 1987 to 1998. Of 127 cancers that were of a well or moderately differentiated type, 67 (53%) were treated using EMR. Of 14 additional operations and nine were treated endoscopically; the remainder had intensive follow up. Local recurrence in the stomach occurred in 17 lesions followed conservatively, in one lesion treated endoscopically, and in five lesions with complete resection. All tumours were diagnosed by follow up endoscopy and subsequently treated by surgery. There were no gastric cancer related deaths during a median follow up period of 38 months (3–120 months). Bleeding and perforation (5%) were two major complications of EMR but there were no treatment related deaths.

Conclusion—In our experience, EMR allows us to perform less invasive treatment without sacrificing the possibility of cure. (Gut 2001;48:225–229)

Keywords: endoscopic mucosal resection; early gastric cancer

Patients and methods

A prospective analysis of 479 EGCs in 445 patients resected by EMR at NCCH, Tokyo, from March 1987 to December 1998 was performed. There were 413 solitary, 17 double, one triple, one quadruple, and 13 metachronous tumours.

Mean age of the patients was 67.6 years (range 34–92), the male to female ratio was 4.13 (357/88), and the follow up period was 3–125 months (median 45 months).

The Japanese Classification of Gastric Carcinoma was used for tumour description. The indications for EMR are determined by the risk of lymph node metastasis and such technical considerations as the size and position of the lesion, and the equipment and expertise available locally. Current indications for EMR at the NCCH are shown in table 1. When EMR was introduced to the NCCH in 1987, the indication size was 15 mm or less in diameter, and multifragment resection was not accepted. However, it was increased to 30 mm because multifragment resection was introduced based on a review of resected cancers and the development of appropriate endoscopic techniques.

Abbreviations used in this paper: EGC, early gastric cancer; EMR, endoscopic mucosal resection; NCCH, National Cancer Center Hospital.
As it is sometimes difficult to accurately assess the depth of invasion prior to EMR, we are prepared to remove any lesion that appears to be confined to the mucosa if it meets the other criteria.

In this series, most EMRs were performed by the so called “strip biopsy method”, a relatively simple technique that has been described elsewhere. Since 1997, a new EMR procedure using an insulation tipped diathermic knife (IT knife) was used in the majority of cases (fig 1).

Follow up endoscopy was performed at three and six months after EMR in the first year, and yearly thereafter to diagnose local recurrence.

**EVALUATION OF RESECTED SPECimens AND RESECTABILITY**

The resectability of EMR specimens was carefully evaluated both endoscopically and histopathologically in slices at 2 mm intervals according to the Japanese Classification of Gastric Carcinoma. After resection in multiple fragments, resectability was evaluated based on completely reconstructed specimens. The current definition of “resection EA”, which means a high probability of cure, is demonstrated in table 2. As submucosal invasion and/or vessel involvement are regarded as high risks of positive nodes or distant metastasis, surgical intervention was strongly recommended.

Evaluation of invasion to the lateral margin was classified into the following three groups using endoscopic and histopathological evidence:

1. **Complete resection**: when the lateral margin was clear endoscopically and pathologically (minimum probability of local recurrence).
2. **Incomplete resection**: when the tumour definitively invaded to the lateral margin endoscopically and pathologically (high probability of local recurrence).
3. **Not evaluable**: when the tumour was removed endoscopically but its lateral margin was not pathologically evaluable due to a burn effect (burned by diathermic treatment) or mechanical damage, or when reconstruction was difficult due to multi-fragment resection.

**STATISTICAL ANALYSIS**

The SAS program (SAS Institute Inc., Cary, North Carolina, USA) was used for all analyses; p<0.05 was taken as significant.

---

**Table 1 Indication criteria for endoscopic mucosal resection**

<table>
<thead>
<tr>
<th>Early gastric cancer meeting all of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Well or moderately differentiated type adenocarcinoma</td>
</tr>
<tr>
<td>(2) Superficial, elevated, or depressed macroscopic appearance (types I, IIa, IIc)</td>
</tr>
<tr>
<td>(3) No ulceration</td>
</tr>
<tr>
<td>(4) Diameter &lt;30 mm</td>
</tr>
<tr>
<td>(5) No apparent invasive findings</td>
</tr>
</tbody>
</table>

**Table 2 Evaluation of resected specimens by endoscopic mucosal resection**

<table>
<thead>
<tr>
<th>The following must be confirmed histologically for “complete resection”:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Intramucosal cancer</td>
</tr>
<tr>
<td>(2) Well or moderately differentiated type adenocarcinoma</td>
</tr>
<tr>
<td>(3) No histological ulceration</td>
</tr>
<tr>
<td>(4) No lymphatic or venous invasion</td>
</tr>
<tr>
<td>(5) No tumour invasion to the lateral margin</td>
</tr>
</tbody>
</table>

---

**Figure 1 Endoscopic mucosal resection procedure using an IT knife.**

(A) Superficial elevated (IIa type) early gastric cancer (EGC) located on the lesser curvature of the lesser body after spraying with indigo carmine dye. (B) Marking dots were made using a precut knife on the circumference of the target lesion to clarify the margin. (C) After injection of saline with epinephrine (0.025 mg/ml) into the submucosal layer, an initial cut was made with a conventional needle knife outside of the dots. The IT knife was inserted into this cut and operated to cut around the lesion. (D) The tumour marked by dots was separated from the surrounding normal mucosa. (E) The tumour was removed by standard polypectomy with a combination of cutting and coagulation current in a single fragment. (F) The resected specimen showed well differentiated adenocarcinoma (20×25 mm) with a clear lateral margin. (G) The specifications of the insulation tipped diathermic knife, which was developed by Dr Hosokawa in 1994. The knife consists of a conventional diathermic needle knife (KD-1L; Olympus, Japan) with a ceramic ball at the top to minimise the risk of perforation.
Table 3 Macroscopic features of the resected tumours

<table>
<thead>
<tr>
<th>Type</th>
<th>Mean</th>
<th>−10</th>
<th>11–20</th>
<th>21–30</th>
<th>31–</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-I type (protruded)</td>
<td>19.7</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>0-IIa type (superficial elevated)</td>
<td>15.7</td>
<td>72</td>
<td>84</td>
<td>21</td>
<td>7</td>
<td>184</td>
</tr>
<tr>
<td>0-IIc type (superficial depressed)</td>
<td>11.2</td>
<td>186</td>
<td>77</td>
<td>14</td>
<td>3</td>
<td>280</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>479</td>
</tr>
</tbody>
</table>

Table 4 Tumour size and invasion to the resection margin of intramucosal cancer

<table>
<thead>
<tr>
<th>Tumour size (mm)</th>
<th>−10</th>
<th>11–20</th>
<th>21–30</th>
<th>31–</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete resection</td>
<td>170 (72%)</td>
<td>86 (67%)</td>
<td>19 (58%)</td>
<td>3 (38%)</td>
<td>278 (69%)</td>
</tr>
<tr>
<td>Incomplete resection</td>
<td>45 (19%)</td>
<td>26 (20%)</td>
<td>12 (36%)</td>
<td>1 (13%)</td>
<td>84 (21%)</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>5 (2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>236 (100%)</td>
<td>128 (100%)</td>
<td>33 (100%)</td>
<td>8 (100%)</td>
<td>405 (100%)</td>
</tr>
</tbody>
</table>

Table 5 Tumour location and invasion to the resection margin of intramucosal cancer

<table>
<thead>
<tr>
<th>Location in the stomach</th>
<th>Lower</th>
<th>Middle</th>
<th>Upper</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete resection</td>
<td>151 (75%)</td>
<td>94 (65%)</td>
<td>33 (57%)</td>
<td>278 (69%)</td>
</tr>
<tr>
<td>Incomplete resection</td>
<td>20 (10%)</td>
<td>17 (12%)</td>
<td>6 (10%)</td>
<td>43 (11%)</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>31 (15%)</td>
<td>34 (23%)</td>
<td>19 (33%)</td>
<td>84 (21%)</td>
</tr>
<tr>
<td>Total</td>
<td>202 (100%)</td>
<td>145 (100%)</td>
<td>58 (100%)</td>
<td>405 (100%)</td>
</tr>
</tbody>
</table>

Results

**Evaluation of Resected Specimens**

The macroscopic appearances of the resected tumours are summarized in Table 3. A total of 429 lesions (90%) were less than 20 mm in diameter while 280 lesions (58%) were of the superficial depressed type (0-IIc type). The tumours were located in the upper third (82 lesions, 17%), middle third (166 lesions, 35%), and lower third (231 lesions, 48%) of the stomach.

Submucosal invasion was found in 74 lesions on subsequent pathological examination by serial sections (Fig 2). These patients were strongly recommended to undergo additional gastrectomy with D2 lymph node dissection. However, 30 patients were merely followed because of minute submucosal invasion, advanced age, other diseases, or the patient’s refusal of an additional operation.

Among 405 intramucosal cancers, 278 (69%) were resected with a clear lateral margin (Table 4). The rate of complete resection was lower when lesions had a diameter exceeding 20 mm and were situated in the upper third of the stomach (tables 4, 5). Forty three tumours were incompletely resected as there was definite invasion to the lateral margin endoscopically and histologically. Although EMR appeared to be successful endoscopically, 84 lesions could not be evaluated histologically because of diathermic burn, mechanical damage, or failure to retrieve multiple fragments.

**Clinical Outcomes (Fig 2)**

Of 278 lesions which were completely resected, five (2%) developed local recurrence, and all were subsequently treated with curative intent. The remainder are disease free at a median follow up period of 38 months (3–120 months).

Of 127 lesions whose “complete resection” was not confirmed, 24 underwent resection and no lymph node metastases were found in these patients, and nine were treated by endoscopic therapy and one developed local recurrence after laser ablation. Among the 95 lesions that were followed conservatively, there were 17 local recurrences (18%) after a median follow up of four months (2–12 months). All of these patients with recurrence underwent surgery and remain disease free. There were no treatment related or gastric cancer related deaths.

**Complications**

Bleeding and perforation were two major complications of EMR. All bleeding was controlled by endoscopic treatment with ethanol injection, endoscopic clipping (HX5LR-1, Olympus, Japan), and spraying of thrombin solution into the stomach. There were 25 cases of perforation (5%); the first four were converted to open surgery. Since then, all perforations have been successfully treated with endoscopic clipping, intubation of a nasogastric tube, and administration of antibiotics.

**Discussion**

The EMR technique has been developed mainly in Japan where there is a high incidence of EGC. It is used infrequently in the West. It is important to carefully evaluate the current status of EMR and promote the appropriate use of this technique around the world. The number of patients undergoing EMR is increasing, with about 500 procedures performed in our hospital over the past 11 years. Considering that it generally takes one hour for resection and one week for admission, EMR is a minimally invasive procedure (a patient undergoing surgical resection is hospitalised for approximately three weeks). Our experience suggests that EMR can provide comparable long term survival rates to traditional therapy, provided adherence to strict inclusion criteria is maintained.
Hospital.

Figure 3 Trends in treatment for early gastric cancer at the National Cancer Center Hospital.

criteria is followed. As shown in fig 3, the proportion of EGC cases treated by EMR at the NCCH has risen, and this accounted for about 40% of all EGC cases in 1998. This is probably due to improved diagnostic techniques.

As there are still several unsolved problems in EMR, we will address specific concerns. Patient eligibility for EMR should be considered in relation to the risk of lymph node metastasis. As shown in table 1, EGCs fulfilling the criteria for EMR have a lower incidence of lymph node metastasis (0.36%) than the mortality rate of surgery for EGC (approximately 0.5% at the NCCH).

In this study, the Japanese Classification of Gastric Carcinoma was used for tumour description, which is widely used in our country. Western pathologists use the term “high grade dysplasia” for neoplastic lesions that have not breached the basement membrane to the lamina propria. Japanese pathologists, however, classify them as intramucosal cancer on the grounds that the cells are of a malignant type and have the potential to invade. A recent analysis showed that the histological type, macroscopic appearance, degree of invasion, and lymph node metastases are the same although many more EGCs are detected in Japan than in the West. We usually perform EMR for intramucosal cancer using the Japanese criteria, and it is important to have the same diagnostic criteria for gastric neoplastic lesions to propagate EMR around the world.

As it is sometimes difficult to accurately assess the depth of invasion prior to EMR, we remove any lesion without apparent endoscopic findings of submucosal invasion but 15% (74/479) of all lesions invaded to the submucosa. We do not use endoscopic ultrasonography routinely as it is not sensitive enough to evaluate minute invasion to the submucosa. Although histological examination revealed minute submucosal invasion in resected EGC, some patients refused to undergo an additional treatment. As no lymph node metastasis was found in patients with minute submucosal invasion by EMR, we will address specific concerns.

A follow up programme is important for finding local recurrence and other cancers in the stomach. Thirteen metachronous early cancers were included in our series, which were diagnosed a median period of 23 months after the initial EMR (3–67 months). The incidence of multiple primary lesions in surgically treated EGC is approximately 10% at the NCCH. As EGC is frequently associated with synchronous tumours that may be missed at an initial endoscopic examination, and the stomach may also contain premalignant conditions such as intestinal metaplasia, we should pay attention not only to recurrence but also to other cancers in the stomach.

In summary, based on our experience, it is clear that EMR can provide the same favourable long term survival rates as traditional therapy and is now the treatment of choice for mucosal EGC. We hope to promote its use around the world.

We are indebted to Drs M Sasako, T Sano, and H Katai, and K Maruyama for helpful suggestions. The work was supported in part by Grants-in-Aid for Cancer Research and for the 2nd Term Comprehensive 10-year Strategy of Cancer Control from the Ministry of Health and Welfare of Japan

Endoscopic mucosal resection for treatment of early gastric cancer

H Ono, H Kondo, T Gotoda, K Shirao, H Yamaguchi, D Saito, K Hosokawa, T Shimoda and S Yoshida

Gut 2001 48: 225-229
doi: 10.1136/gut.48.2.225

Updated information and services can be found at:
http://gut.bmj.com/content/48/2/225

These include:

References
This article cites 14 articles, 1 of which you can access for free at:
http://gut.bmj.com/content/48/2/225#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Pancreatic cancer (660)
- Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/